Adoption of electronic government in bahia blanca during the period 2019-2020: an exploratory analysis

En la mayoría de las ciudades de la región desde hace unos años se han observado importantes avances en el acceso y uso de las Tecnologías de la Información y de la Comunicación en la administración pública. Si bien son conocidos las ventajas y beneficios que tienen las mismas, la literatura sobre gobierno electrónico se ha centrado, principalmente, en explorar los servicios públicos desde el lado de la oferta, siendo la perspectiva del ciudadano poco analizada. Este trabajo explora el nivel de adopción del gobierno electrónico desde la perspectiva del ciudadano. Se busca analizar cuán involucrados están los ciudadanos de Bahía Blanca con el gobierno electrónico (mediante el sitio web municipal) así como explorar los factores subjetivos que influyen en su adopción. Asimismo, se estudia el impacto de la pandemia por el COVID-19 en dicha adopción y se intenta observar si la misma ha influenciado en potenciar el gobierno electrónico en la ciudad. La recopilación de estos datos fue efectuada mediante dos relevamientos online, realizados a través de cuestionarios de preguntas cerradas. El primero de ellos fue llevado a cabo a través de la red social Facebook, específicamente a los seguidores de la fanpage Facebook Moderniza Bahía mientras en el segundo consistió en un formulario que podía ser respondido por cualquier habitante de la localidad. De los resultados obtenidos se desprende que el alto nivel educativo está asociado con un mayor nivel de adopción de Gobierno Electrónico. Por otra parte, respecto del género y la adopción de herramientas digitales que ofrece el municipio, resulta significativa la diferencia entre hombres y mujeres.In the majority of the cities of the region, in recent years there have been important advances in the access and use of Information and Communication Technologies in the public administration. Although the advantages and benefits that they have are known, the literature on electronic government has focused mainly on exploring public services from the supply side, with the perspective of the citizen being little analyzed. This work explores the level of adoption of electronic government from the perspective of the citizen. It seeks to analyze how involved the citizens of Bahía Blanca are with electronic government (through the municipal website) as well as explore the subjective factors that influence its adoption. Likewise, the impact of the COVID-19 pandemic on said adoption is studied and an attempt is made to observe if it has influenced the enhancement of electronic government in the city. The collection of these data was carried out through two online surveys, carried out through questionnaires with closed questions. The first of them was carried out through the social network Facebook, specifically to the followers of the Moderniza Bahía fanpage, while the second consisted of a form that could be answered by any inhabitant of the town. The results obtained show that the high educational level is associated with a higher level of adoption of Electronic Government. On the other hand, regarding gender and the adoption of digital tools offered by the municipality, the difference between men and women is significant.Fil: Diaz, Lucia Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Investigaciones Económicas y Sociales del Sur. Universidad Nacional del Sur. Departamento de Economía. Instituto de Investigaciones Económicas y Sociales del Sur; ArgentinaFil: Gutierrez, Emiliano Martin. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Investigaciones Económicas y Sociales del Sur. Universidad Nacional del Sur. Departamento de Economía. Instituto de Investigaciones Económicas y Sociales del Sur; Argentin

Multi-Omic Biomarkers for Patient Stratification in Sjogren's Syndrome—A Review of the Literature

Sjögren's syndrome (SS) is a heterogeneous autoimmune rheumatic disease (ARD) characterised by dryness due to the chronic lymphocytic infiltration of the exocrine glands. Patients can also present other extra glandular manifestations, such as arthritis, anaemia and fatigue or various types of organ involvement. Due to its heterogenicity, along with the lack of effective treatments, the diagnosis and management of this disease is challenging. The objective of this review is to summarize recent multi-omic publications aiming to identify biomarkers in tears, saliva and peripheral blood from SS patients that could be relevant for their better stratification aiming at improved treatment selection and hopefully better outcomes. We highlight the relevance of pro-inflammatory cytokines and interferon (IFN) as biomarkers identified in higher concentrations in serum, saliva and tears. Transcriptomic studies confirmed the upregulation of IFN and interleukin signalling in patients with SS, whereas immunophenotyping studies have shown dysregulation in the immune cell population frequencies, specifically CD4+and C8+T activated cells, and their correlations with clinical parameters, such as disease activity scores. Lastly, we discussed emerging findings derived from different omic technologies which can provide integrated knowledge about SS pathogenesis and facilitate personalised medicine approaches leading to better patient outcomes in the future

Systematic evaluation of cryptic freshwater snails from central Chile, including the enigmatic Littoridina santiagensis (Gastropoda, Truncatelloidea)

In 1944, Walter Biese described Littoridina santiagensis (Cochliopidae) from Estero Dehesa based exclusively on external shell features and a second allopatric population in Yeso Spring three years later. Different samplings carried out since 2011 in the type locality have only provided specimens of the morphologically similar invasive mudsnail Potamopyrgus antipodarum (Tateidae) raising doubts about the identity of the species. The recent finding of two snail morphotypes in Yeso Spring, a thick shelled form congruent with type specimens of L. santiagensis and a slender one morphologically associable to P. antipodarum, allowed comparative studies, including the taxonomic analysis of additional populations with similar shell morphology occurring in central Chile. A DNA barcoding (COI) approach identified the slender form from Yeso Spring in Maipo Basin and a second population from the contiguous Rapel Basin indeed as the invasive P. antipodarum, however, L. santiagensis was recovered among species of Potamolithus (Tateidae) justifying the binomem Potamolithus santiagensis as a new combination. Besides recognition of other three populations as belonging to Potamolithus, the molecular analysis also suggests trans-Andean dispersal of this group of snails in the Southern Cone of South America.Fil: Collado, Gonzalo A.. Universidad del Bio Bio; ChileFil: Aguayo, Karina P.. Universidad del Bio Bio; ChileFil: Cazzaniga, Néstor Jorge. Universidad Nacional del Sur; ArgentinaFil: Gutierrez Gregoric, Diego Eduardo. Universidad Nacional de La Plata. Facultad de Ciencias Naturales y Museo. División Invertebrados; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; ArgentinaFil: de Lucia, Micaela. Provincia de Buenos Aires. Gobernación. Comisión de Investigaciones Científicas; Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Naturales y Museo. División Invertebrados; ArgentinaFil: Haase, Martin. University of Greifswald; Alemani

Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.

BACKGROUND: The causes of phenotypic heterogeneity in familial Alzheimer's disease with autosomal dominant inheritance are not well understood. We aimed to characterise clinical phenotypes and genetic associations with APP and PSEN1 mutations in symptomatic autosomal dominant familial Alzheimer's disease (ADAD). METHODS: We retrospectively analysed genotypic and phenotypic data (age at symptom onset, initial cognitive or behavioural symptoms, and presence of myoclonus, seizures, pyramidal signs, extrapyramidal signs, and cerebellar signs) from all individuals with ADAD due to APP or PSEN1 mutations seen at the Dementia Research Centre in London, UK. We examined the frequency of presenting symptoms and additional neurological features, investigated associations with age at symptom onset, APOE genotype, and mutation position, and explored phenotypic differences between APP and PSEN1 mutation carriers. The proportion of individuals presenting with various symptoms was analysed with descriptive statistics, stratified by mutation type. FINDINGS: Between July 1, 1987, and Oct 31, 2015, age at onset was recorded for 213 patients (168 with PSEN1 mutations and 45 with APP mutations), with detailed history and neurological examination findings available for 121 (85 with PSEN1 mutations and 36 with APP mutations). We identified 38 different PSEN1 mutations (four novel) and six APP mutations (one novel). Age at onset differed by mutation, with a younger onset for individuals with PSEN1 mutations than for those with APP mutations (mean age 43·6 years [SD 7·2] vs 50·4 years [SD 5·2], respectively, p<0·0001); within the PSEN1 group, 72% of age at onset variance was explained by the specific mutation. A cluster of five mutations with particularly early onset (mean age at onset <40 years) involving PSEN1's first hydrophilic loop suggests critical functional importance of this region. 71 (84%) individuals with PSEN1 mutations and 35 (97%) with APP mutations presented with amnestic symptoms, making atypical cognitive presentations significantly more common in PSEN1 mutation carriers (n=14; p=0·037). Myoclonus and seizures were the most common additional neurological features; individuals with myoclonus (40 [47%] with PSEN1 mutations and 12 [33%] with APP mutations) were significantly more likely to develop seizures (p=0·001 for PSEN1; p=0·036 for APP), which affected around a quarter of the patients in each group (20 [24%] and nine [25%], respectively). A number of patients with PSEN1 mutations had pyramidal (21 [25%]), extrapyramidal (12 [14%]), or cerebellar (three [4%]) signs. INTERPRETATION: ADAD phenotypes are heterogeneous, with both age at onset and clinical features being influenced by mutation position as well as causative gene. This highlights the importance of considering genetic testing in young patients with dementia and additional neurological features in order to appropriately diagnose and treat their symptoms, and of examining different mutation types separately in future research. FUNDING: Medical Research Council and National Institute for Health Research

Artificial Intelligence and Digital Transformation: early lessons from the COVID-19 crisis

The COVID-19 pandemic has created an extraordinary medical, economic and social emergency. To contain the spread of the virus, many countries adopted a lock down policy closing schools and business and keeping people at home for several months. This resulted in a massive surge of activity online for education, business, public administration, research, social interaction. This report considers these recent developments and identifies some early lessons with respect to the present and future development of AI and digital transformation in Europe, focusing in particular on data, as this is an area of significant shifts in attitudes and policy. The report analyses the increasing use of AI in medicine and healthcare, the tensions in data sharing between individual rights and collective wellbeing, the search for technological solutions like contact tracing apps to help monitor the spread of the virus, and the potential concerns they raise. The forced transition to online showed the resilience of the Internet but also the disproportionate impact on already vulnerable groups like the elderly and children. The report concludes that the COVID-19 crisis has acted as a boost for AI adoption and data sharing, and created new opportunities. It has also amplified concerns for democracy and social inequality and showed Europe’s vulnerability on data and platforms, calling for action to address these crucial aspects.JRC.B.6-Digital Econom

Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial

Introduction:Decreased plasma vitamin D (VD) levels are linked to cardiovascular damage. However, clinical trials have not demonstrated a benefit of VD supplements on left ventricular (LV) remodelling. Anterior ST-elevation acute myocardial infarction (STEMI) is the best human model to study the effect of treatments on LV remodelling. We present a proof-of-concept study that aims to investigate whether VD improves LV remodelling in patients with anterior STEMI. Methods and analysis:The VITamin D in Acute Myocardial Infarction (VITDAMI) trial is a multicentre, randomised, double-blind, placebo-controlled trial. 144 patients with anterior STEMI will be assigned to receive calcifediol 0.266 mg capsules (Hidroferol SGC)/15 days or placebo on a 2:1 basis during 12 months. Primary objective:to evaluate the effect of calcifediol on LV remodelling defined as an increase in LV end-diastolic volume >= 10\% (MRI). Secondary objectives:change in LV end-diastolic and end-systolic volumes, ejection fraction, LV mass, diastolic function, sphericity index and size of fibrotic area; endothelial function; plasma levels of aminoterminal fragment of B-type natriuretic peptide, galectin-3 and monocyte chemoattractant protein-1; levels of calcidiol (VD metabolite) and other components of mineral metabolism (fibroblast growth factor-23 (FGF-23), the soluble form of its receptor klotho, parathormone and phosphate). Differences in the effect of VD will be investigated according to the plasma levels of FGF-23 and klotho. Treatment safety and tolerability will be assessed. This is the first study to evaluate the effect of VD on cardiac remodelling in patients with STEMI. Ethics and dissemination: This trial has been approved by the corresponding Institutional Review Board (IRB) and National Competent Authority (Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS)). It will be conducted in accordance with good clinical practice (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use-Good Clinical Practice (ICH-GCP)) requirements, ethical principles of the Declaration of Helsinki and national laws. The results will be submitted to indexed medical journals and national and international meetings.The VITDAMI trial is an investigator initiated study, sponsored by the Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD). Funding has been obtained from Fondo de Investigaciones Sanitarias (PI14/01567; http://www.isciii.es/) and Spanish Society of Cardiology (http://secardiologia.es/). In addition, the study medication has been provided freely by the pharmaceutical Company FAES FARMA S.A. (Leioa, Vizcaya, Spain; http://faesfarma.com/). This company was the only funder who collaborated in study design (IG-H).S

Artificial Intelligence: A European Perspective

We are only at the beginning of a rapid period of transformation of our economy and society due to the convergence of many digital technologies. Artificial Intelligence (AI) is central to this change and offers major opportunities to improve our lives. The recent developments in AI are the result of increased processing power, improvements in algorithms and the exponential growth in the volume and variety of digital data. Many applications of AI have started entering into our every-day lives, from machine translations, to image recognition, and music generation, and are increasingly deployed in industry, government, and commerce. Connected and autonomous vehicles, and AI-supported medical diagnostics are areas of application that will soon be commonplace. There is strong global competition on AI among the US, China, and Europe. The US leads for now but China is catching up fast and aims to lead by 2030. For the EU, it is not so much a question of winning or losing a race but of finding the way of embracing the opportunities offered by AI in a way that is human-centred, ethical, secure, and true to our core values. The EU Member States and the European Commission are developing coordinated national and European strategies, recognising that only together we can succeed. We can build on our areas of strength including excellent research, leadership in some industrial sectors like automotive and robotics, a solid legal and regulatory framework, and very rich cultural diversity also at regional and sub-regional levels. It is generally recognised that AI can flourish only if supported by a robust computing infrastructure and good quality data: • With respect to computing, we identified a window of opportunity for Europe to invest in the emerging new paradigm of computing distributed towards the edges of the network, in addition to centralised facilities. This will support also the future deployment of 5G and the Internet of Things. • With respect to data, we argue in favour of learning from successful Internet companies, opening access to data and developing interactivity with the users rather than just broadcasting data. In this way, we can develop ecosystems of public administrations, firms, and civil society enriching the data to make it fit for AI applications responding to European needs. We should embrace the opportunities afforded by AI but not uncritically. The black box characteristics of most leading AI techniques make them opaque even to specialists. AI systems are currently limited to narrow and well-defined tasks, and their technologies inherit imperfections from their human creators, such as the well-recognised bias effect present in data. We should challenge the shortcomings of AI and work towards strong evaluation strategies, transparent and reliable systems, and good human-AI interactions. Ethical and secure-by-design algorithms are crucial to build trust in this disruptive technology, but we also need a broader engagement of civil society on the values to be embedded in AI and the directions for future development. This social engagement should be part of the effort to strengthen our resilience at all levels from local, to national and European, across institutions, industry and civil society. Developing local ecosystems of skills, computing, data, and applications can foster the engagement of local communities, respond to their needs, harness local creativity and knowledge, and build a human-centred, diverse, and socially driven AI. We still know very little about how AI will impact the way we think, make decisions, relate to each other, and how it will affect our jobs. This uncertainty can be a source of concern but is also a sign of opportunity. The future is not yet written. We can shape it based on our collective vision of what future we would like to have. But we need to act together and act fast.JRC.B.6-Digital Econom

Коротка історія Радянської Соціалістичної Республіки Тавріди (1918 р.)

Familial Alzheimer's disease (FAD) treatment trials raise interest in the variable occurrence of cerebral amyloid angiopathy (CAA); an emerging important factor in amyloid-modifying therapy. Previous pathological studies reported particularly severe CAA with postcodon 200 PSEN1 mutations and amyloid beta coding domain APP mutations. As CAA may manifest as white matter hyperintensities (WMH) on magnetic resonance imaging, particularly posteriorly, we investigated WMH in 52 symptomatic FAD patients for associations with mutation position. WMH were visually rated in 39 PSEN1 (18 precodon 200); 13 APP mutation carriers and 25 healthy controls. Ten PSEN1 mutation carriers (5 precodon 200) had postmortem examination. Increased WMH were observed in the PSEN1 postcodon 200 group and in the single APP patient with an amyloid beta coding domain (p.Ala692Gly, Flemish) mutation. WMH burden on MRI correlated with severity of CAA and cotton wool plaques in several areas. The precodon 200 group had younger ages at onset, decreased axonal density and/or integrity, and a greater T-lymphocytic response in occipital deep white matter. Mutation site contributes to the phenotypic and pathological heterogeneity witnessed in FAD

Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade

Age-associated B cells (ABC) accumulate with age and in individuals with different immunological disorders, including cancer patients treated with immune checkpoint blockade and those with inborn errors of immunity. Here, we investigate whether ABCs from different conditions are similar and how they impact the longitudinal level of the COVID-19 vaccine response. Single-cell RNA sequencing indicates that ABCs with distinct aetiologies have common transcriptional profiles and can be categorised according to their expression of immune genes, such as the autoimmune regulator (AIRE). Furthermore, higher baseline ABC frequency correlates with decreased levels of antigen-specific memory B cells and reduced neutralising capacity against SARS-CoV-2. ABCs express high levels of the inhibitory FcγRIIB receptor and are distinctive in their ability to bind immune complexes, which could contribute to diminish vaccine responses either directly, or indirectly via enhanced clearance of immune complexed-antigen. Expansion of ABCs may, therefore, serve as a biomarker identifying individuals at risk of suboptimal responses to vaccination

Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients

A better understanding of schizophrenia subtypes is necessary to stratify the patients according to clinical attributes. To explore the genomic architecture of schizophrenia symptomatology, we analyzed blood co-expression modules and their association with clinical data from patients in remission after a first episode of schizophrenia. In total, 91 participants of the 2EPS project were included. Gene expression was assessed using the Clariom S Human Array. Weighted-gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its correlation with global functioning, clinical symptomatology, and premorbid adjustment. Among the 25 modules identified, six modules were significantly correlated with clinical data. These modules could be clustered in two groups according to their correlation with clinical data. Hub genes in each group showing overlap with risk genes for schizophrenia were enriched in biological processes related to metabolic processes, regulation of gene expression, cellular localization and protein transport, immune processes, and neurotrophin pathways. Our results indicate that modules with significant associations with clinical data showed overlap with gene sets previously identified in differential gene-expression analysis in brain, indicating that peripheral tissues could reveal pathogenic mechanisms. Hub genes involved in these modules revealed multiple signaling pathways previously related to schizophrenia, which may represent the complex interplay in the pathological mechanisms behind the disease. These genes could represent potential targets for the development of peripheral biomarkers underlying illness traits in clinical remission stages after a first episode of schizophrenia